Published in Clin Microbiol Rev on October 01, 2010
Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest (2011) 1.82
Point: is the era of viral culture over in the clinical microbiology laboratory? J Clin Microbiol (2012) 1.64
The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol (2011) 1.25
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. J Clin Virol (2011) 1.19
Multidrug resistance: an emerging crisis. Interdiscip Perspect Infect Dis (2014) 1.17
First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother (2012) 1.12
The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis. Infect Disord Drug Targets (2011) 1.10
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother (2010) 1.10
The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis (2011) 1.10
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother (2013) 1.05
Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol (2013) 1.04
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. Antimicrob Agents Chemother (2015) 1.00
Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev (2013) 0.99
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother (2011) 0.98
Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol (2011) 0.95
Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci U S A (2015) 0.94
Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother (2013) 0.93
Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. Antimicrob Agents Chemother (2011) 0.92
Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob Agents Chemother (2013) 0.92
Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res (2011) 0.91
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother (2011) 0.91
In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother (2011) 0.91
Live or let die: manipulation of cellular suicide programs by murine cytomegalovirus. Med Microbiol Immunol (2012) 0.90
Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus. J Virol (2013) 0.89
Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J Clin Microbiol (2013) 0.89
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother (2013) 0.89
Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J Infect Dis (2013) 0.87
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother (2014) 0.87
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother (2013) 0.87
Phosphorylation events during viral infections provide potential therapeutic targets. Rev Med Virol (2011) 0.86
Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. J Clin Microbiol (2014) 0.85
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. Antimicrob Agents Chemother (2013) 0.85
Unexpected features and mechanism of heterodimer formation of a herpesvirus nuclear egress complex. EMBO J (2015) 0.85
Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother (2013) 0.85
Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc Natl Acad Sci U S A (2014) 0.85
Utility of the bacteriophage RB69 polymerase gp43 as a surrogate enzyme for herpesvirus orthologs. Viruses (2013) 0.85
Differentiated levels of ganciclovir resistance conferred by mutations at codons 591-603 of the cytomegalovirus UL97 kinase gene. J Clin Microbiol (2017) 0.85
Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist (2015) 0.84
Emerging rapid resistance testing methods for clinical microbiology laboratories and their potential impact on patient management. Biomed Res Int (2014) 0.84
Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene. Antimicrob Agents Chemother (2012) 0.84
Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res (2011) 0.84
Temporal and spatial compartmentalization of drug-resistant cytomegalovirus (CMV) in a child with CMV meningoencephalitis: implications for sampling in molecular diagnosis. J Clin Microbiol (2013) 0.83
Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent. Drugs Future (2013) 0.83
Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis (2013) 0.82
Cytomegalovirus antivirals and development of improved animal models. Expert Opin Drug Metab Toxicol (2011) 0.81
Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective. Recent Pat Antiinfect Drug Discov (2013) 0.81
Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation. Front Immunol (2015) 0.81
In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. Antimicrob Agents Chemother (2013) 0.80
Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase. Nucleic Acids Res (2016) 0.80
Cytomegalovirus infection in liver transplant recipients: updates on clinical management. World J Gastroenterol (2014) 0.80
Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. J Infect Dis (2016) 0.80
Murine cytomegalovirus infection of mouse macrophages stimulates early expression of suppressor of cytokine signaling (SOCS)1 and SOCS3. PLoS One (2017) 0.80
Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. Comput Struct Biotechnol J (2015) 0.79
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. Antimicrob Agents Chemother (2016) 0.78
Cytomegalovirus Treatment. Curr Treat Options Infect Dis (2015) 0.78
Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility. J Virol (2015) 0.78
Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis (2015) 0.78
Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunology (2015) 0.78
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation (2016) 0.78
Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives. Antimicrob Agents Chemother (2013) 0.78
Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago. Case Rep Nephrol Dial (2015) 0.78
Current aspects on the management of viral uveitis in immunocompetent individuals. Clin Ophthalmol (2015) 0.77
Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. J Clin Microbiol (2011) 0.77
In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother (2015) 0.77
Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol (2013) 0.77
Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses. Antimicrob Agents Chemother (2014) 0.77
KSHV targeted therapy: an update on inhibitors of viral lytic replication. Viruses (2014) 0.77
Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation. Antimicrob Agents Chemother (2015) 0.76
Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. Antiviral Res (2016) 0.76
Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. J Clin Microbiol (2012) 0.76
Role of human cytomegalovirus tegument proteins in virion assembly. Viruses (2014) 0.76
Novel heparan sulfate-binding peptides for blocking herpesvirus entry. PLoS One (2015) 0.76
2-(2,4-Dioxy-1,2,3,4-Tetrahydropyrimidin-1-yl)-N-(4-Phenoxyphenyl)-Acetamides as a Novel Class of Cytomegalovirus Replication Inhibitors. Acta Naturae (2016) 0.75
γδ T Cell-Mediated Immunity to Cytomegalovirus Infection. Front Immunol (2017) 0.75
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood (2016) 0.75
Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus. J Clin Microbiol (2016) 0.75
Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samples. J Clin Microbiol (2013) 0.75
Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection. Case Rep Transplant (2017) 0.75
Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients. Jundishapur J Microbiol (2016) 0.75
Human embryonic lung fibroblasts treated with artesunate exhibit reduced rates of proliferation and human cytomegalovirus infection in vitro. J Thorac Dis (2015) 0.75
The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro. Antiviral Res (2016) 0.75
Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients. J Clin Virol (2015) 0.75
Impact of a cytomegalovirus kinase inhibitor on infection and neuronal progenitor cell differentiation. Antiviral Res (2016) 0.75
Late emergence of A594V and L595W mutations related to ganciclovir resistance in a patient with HCMV retinitis and long-term HIV progression. Braz J Med Biol Res (2015) 0.75
Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus. PLoS Pathog (2016) 0.75
Long and Short Isoforms of the Human Cytomegalovirus UL138 Protein Silence IE Transcription and Promote Latency. J Virol (2016) 0.75
Antiviral drug resistance as an adaptive process. Virus Evol (2016) 0.75
Incidence of Ganciclovir Resistance in CMV-positive Renal Transplant Recipients and its Association with UL97 Gene Mutations. Iran J Pharm Res (2017) 0.75
Drug Susceptibility and Replicative Capacity of Multi-Drug Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes. Antimicrob Agents Chemother (2017) 0.75
The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science (1988) 35.59
Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res (2005) 11.23
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol (1996) 6.64
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res (2007) 5.95
Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis (2006) 5.71
Compilation, alignment, and phylogenetic relationships of DNA polymerases. Nucleic Acids Res (1993) 5.31
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis (2009) 4.48
Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A (2003) 4.37
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis (2010) 3.61
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (1992) 3.59
Genetic content of wild-type human cytomegalovirus. J Gen Virol (2004) 3.58
Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr (2003) 3.38
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis (2009) 3.08
9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A (1983) 3.03
Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J Gen Virol (1989) 3.01
Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature (1992) 2.98
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother (2002) 2.98
How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86
Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med (1989) 2.77
Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis (1995) 2.65
Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (1999) 2.63
A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol (1999) 2.58
Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol (1998) 2.41
A general structure for DNA-dependent DNA polymerases. Gene (1991) 2.27
The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol (2003) 2.21
Ganciclovir. N Engl J Med (1996) 2.19
The dynamics of human cytomegalovirus replication in vivo. J Exp Med (1999) 2.19
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis (1997) 2.18
A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother (1993) 2.16
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis (1997) 2.14
Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci U S A (2001) 2.10
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol (2004) 2.08
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol (2001) 2.07
The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J Virol (1997) 2.06
Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis (2003) 2.00
Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat (2002) 2.00
Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science (2008) 1.99
Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem (2006) 1.98
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs (1991) 1.96
Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother (2005) 1.91
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev (2003) 1.91
Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev (2009) 1.90
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis (2001) 1.85
Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother (2005) 1.83
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother (2003) 1.83
Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog (2009) 1.82
Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol (1992) 1.81
Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis (1998) 1.80
Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother (2004) 1.79
A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A (1986) 1.78
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis (2001) 1.77
Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J Biol Chem (2005) 1.77
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother (2002) 1.75
Cytomegalovirus in solid organ transplant recipients. Am J Transplant (2009) 1.74
Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant (2005) 1.73
In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother (2005) 1.72
A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol (1995) 1.71
Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis (1995) 1.71
Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J (2003) 1.70
Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr (2010) 1.64
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation (2006) 1.63
The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol (1996) 1.63
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis (2007) 1.61
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol (2001) 1.59
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis (1997) 1.56
Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother (2009) 1.55
Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother (1995) 1.55
Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res (2009) 1.55
The antiviral activities of artemisinin and artesunate. Clin Infect Dis (2008) 1.55
Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol (1994) 1.52
Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol (2005) 1.51
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis (2007) 1.51
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol (2008) 1.49
Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother (1998) 1.49
Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol (2008) 1.48
Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest (1995) 1.47
Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol (2010) 1.45
Primary structure of the catalytic subunit of calf thymus DNA polymerase delta: sequence similarities with other DNA polymerases. Biochemistry (1991) 1.44
The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol (2003) 1.42
Characterization of human cytomegalovirus-induced DNA polymerase and the associated 3'-to-5', exonuclease. Virology (1983) 1.42
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med (2002) 1.39
The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology (2003) 1.38
Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother (1999) 1.38
A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J Virol Methods (1990) 1.37
In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother (2010) 1.36
Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J Virol (2007) 1.36
Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother (2001) 1.36
Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J Virol Methods (1990) 1.36
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother (2010) 1.34
High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J Gen Virol (2009) 1.34
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 1.78
Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog (2007) 1.29
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother (2006) 1.28
Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis (2003) 1.28
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis (2008) 1.23
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol (2005) 1.21
Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts. Virol J (2006) 1.13
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis (2003) 1.10
The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis (2011) 1.10
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol (2006) 1.08
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol (2013) 1.04
Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis (2010) 1.01
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci (2002) 0.99
Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J (2009) 0.94
Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment. J Virol (2011) 0.92
Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res (2011) 0.91
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol (2006) 0.91
Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol (2014) 0.87
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. Antimicrob Agents Chemother (2013) 0.85
Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol J (2006) 0.85
Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res (2011) 0.84
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. J Clin Virol (2004) 0.84
Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology (2005) 0.84
Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am (2010) 0.83
Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am (2010) 0.82
Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol (2002) 0.82
Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol (2009) 0.81
Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis. J Infect Dis (2002) 0.81
Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl (2003) 0.79
A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation (2002) 0.79
DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun (2003) 0.79
Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients. Transfusion (2003) 0.75